RE:RE:RE:RE:RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerPfizer continues to advance its aim of developing next generation therapies and has initiated a Phase 3 trial that will evaluate a combination of its novel CDK4 inhibitor PF-07220060 and Faslodex versus investigator's choice of Faslodex alone or everolimus plus exemestane in advanced or metastatic HR-positive/HER2-negative breast cancer patients progressed on prior CDK4/6 inhibitor-based therapy.
Both Roche and Pfizer are actively pursuing the development and inclusion of novel treatments into their breast cancer portfolios, into which ONCY's pelareorep fits nicely as a immunomodulator that is able to remodel the cancer's TME and stimulate the immune system to upregulate TiLs that facilitate the sequencing-in of immune checkpoint inhibitors and the preclusion of T cell exhastion.
https://clinicaltrials.gov/study/NCT06105632